[{"from": "human", "value": "Describe this molecule. [C][C@H1][Branch2][Ring1][C][C][C][C][=Branch1][C][=O][N][C][C][S][=Branch1][C][=O][=Branch1][C][=O][O][C@H1][C][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring1][=N][C][C][C@H1][C@H1][Ring1][=Branch1][C@H1][Branch2][Ring1][C][C][C@H1][C@@][Ring1][=Branch1][Branch1][#Branch2][C][C][C@H1][Branch1][Ring2][C][Ring1][=Branch1][O][C][O][C]"}, {"from": "gpt", "value": "The molecule is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of [ursodeoxycholic acid] with comparable therapeutic efficacy and safety, but a much higher hydrophilicity. Normally, hydrophilic bile acids regulates hydrophobic bile acids and their cytotoxic effects. Tauroursodeoxycholic acid can reduce the absorption of cholesterol in the small intestine, thereby reducing the body's intake of dietary cholesterol and the body cholesterol content.  Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases."}]